Real-world first-line outcomes of alectinib and brigatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: a nationwide South Korean cohort study using the health insurance review and assessment data

Hee Jun Kim, Eunyoung Angela Lee, Jin-Hee Park, Hyun Woo Lee · 2025

Read Real-world first-line outcomes of alectinib and brigatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: a nationwide South Korean cohort study using the health insurance review and assessment data by Hee Jun Kim, Eunyoung Angela Lee, Jin-Hee Park, Hyun Woo Lee (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12683494.txt.

Description

BackgroundLung cancer remains the leading cause of cancer-related mortality worldwide. Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) presents unique clinical challenges, including frequent central nervous system (CNS) metastases. At present, comparative real-world data on ALK inhibitors remain limited.

Catalog record

CREATORHee Jun Kim, Eunyoung Angela Lee, Jin-Hee Park, Hyun Woo Lee
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12683494

Browse the full library · About the Tower of Babel